{
    "clinical_study": {
        "@rank": "8297", 
        "arm_group": [
            {
                "arm_group_label": "Sequence (Group) 1", 
                "arm_group_type": "Experimental", 
                "description": "Subjects randomized to Sequence 1 will receive TI in the following sequence:\nTI-Inhalation Powder A TI-Inhalation Powder B\n*30 units (10 units + 20 units)"
            }, 
            {
                "arm_group_label": "Sequence (Group) 2", 
                "arm_group_type": "Experimental", 
                "description": "Subjects randomized to Sequence 2 will receive TI in the following sequence:\nTI-Inhalation Powder B TI-Inhalation Powder A\n*30 units (10 units + 20 units)"
            }
        ], 
        "brief_summary": {
            "textblock": "A Phase 1, open-label randomized crossover trial in Healthy Volunteers to evaluate the PK/PD\n      of TI (Technosphere\u00ae Insulin) prepared with insulin from two different suppliers."
        }, 
        "brief_title": "Comparison of 30 Units of TI (Technosphere\u00ae Insulin) Prepared With Insulin From Two Different Suppliers", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men and women aged 18 to 55 years, considered healthy based on screening physical\n             examination, medical history, clinical chemistry, and urinalysis\n\n               -  HNVs with a screening blood pressure less than 140/90 mm Hg\n\n               -  Subjects who have hypertension controlled with up to 1 medication and who have a\n                  blood pressure less than 140/90 mm Hg\n\n               -  Note: For subjects with blood pressure at or above 140/90 mm Hg; two additional\n                  readings 5 minutes apart are allowed but the last blood pressure reading must be\n                  in range\n\n               -  Subjects who have hypercholesterolemia controlled with up to 1 medication and\n                  who have a low-density lipoprotein value less than 160 mg/dL\n\n          -  Good venous access for blood draws\n\n          -  No smoking in the past 6 months (including cigarettes, cigars, and pipes) and urine\n             cotinine testing < 100 ng/mL\n\n          -  Body mass index (BMI) < 32 kg/m2\n\n          -  Completion of informed consent form\n\n        Exclusion Criteria:\n\n          -  Blood donation (500 mL) within the last 8 weeks\n\n          -  Fasting blood sugar >100 mg/dL\n\n          -  History of coronary artery disease, peripheral vascular disease, or congestive heart\n             failure\n\n          -  Allergy to study drug, components of Boost and Boost Plus, or other study material\n\n          -  Clinically significant active or chronic illness\n\n          -  History of asthma, COPD, or any other clinically relevant chronic lung disease\n\n          -  Respiratory tract infection within 4 weeks before screening\n\n          -  History of drug or alcohol abuse within the past 5 years\n\n          -  Positive urine drug screen\n\n          -  Clinically significant screening ECG, physical examination, laboratory test, or vital\n             sign abnormality\n\n          -  Exposure to any other investigational drug or device within 30 days before treatment\n             or within 90 days before treatment for drugs known to modify glucose metabolism\n\n          -  History of malignancy within the 5 years before screening (other than basal cell\n             carcinoma)\n\n          -  History of human immunodeficiency virus (HIV) infection or hepatitis B or C\n\n          -  Women who are pregnant, lactating, or planning to become pregnant during the clinical\n             study period\n\n          -  Women of childbearing potential (premenopausal who have not undergone hysterectomy or\n             bilateral tubal ligation, or postmenopausal for fewer than 2 years) not practicing\n             adequate birth control. Adequate birth control is defined as using oral,\n             percutaneous, or transdermal contraceptives; condoms and diaphragms (double barrier)\n             with a spermicide; or intrauterine devices. Postmenopausal for the purposes of this\n             clinical study includes experiencing amenorrhea for 2 or more years or being\n             surgically sterile.\n\n          -  Any subject who, in the opinion of the PI or a designee, appears not to be qualified\n             for this study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01982604", 
            "org_study_id": "MKC-TI-179"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Sequence (Group) 1", 
                    "Sequence (Group) 2"
                ], 
                "description": "Inhaled Insulin", 
                "intervention_name": "TI-Inhalation Powder A", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Sequence (Group) 1", 
                    "Sequence (Group) 2"
                ], 
                "description": "Inhaled Insulin", 
                "intervention_name": "TI-Inhalation Powder B", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Insulin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 10, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Chula Vista", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "91911"
                }
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1, Open-label, Randomized, Crossover Clinical Trial to Evaluate PK/PD of 30 U TI Inhalation Powders Prepared With Insulin From Two Different Suppliers", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "AUC (area-under-the-serum-insulin concentration time curve) 0 - 240 minutes", 
                "safety_issue": "No", 
                "time_frame": "5, 10, 15, 20, 25, 30, 45, 60, 75, 90, 120, 150,  210, 240"
            }, 
            {
                "measure": "Cmax (maximum serum insulin concentration)", 
                "safety_issue": "No", 
                "time_frame": "5, 10, 15, 20, 25, 30, 45, 60, 75, 90, 120, 150,  210, 240"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01982604"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "GIR (area-under-the-serum Glucose Infusion Rate)", 
            "safety_issue": "No", 
            "time_frame": "0 to 360"
        }, 
        "source": "Mannkind Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mannkind Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}